Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.

McBride JW, Malcolm RK, Dias N, Cameron D, Offord RE, Hartley O, Kett VL, Devlin B, Boyd P.

Int J Pharm. 2019 Jun 10;564:207-213. doi: 10.1016/j.ijpharm.2019.04.040. Epub 2019 Apr 15.

PMID:
30999049
2.

Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES.

McBride JW, Boyd P, Dias N, Cameron D, Offord RE, Hartley O, Kett VL, Malcolm RK.

J Control Release. 2019 Mar 28;298:1-11. doi: 10.1016/j.jconrel.2019.02.003. Epub 2019 Feb 4.

3.

Experiences of loss and relationship quality in couples living with dementia.

Colquhoun A, Moses J, Offord R.

Dementia (London). 2019 Aug;18(6):2158-2172. doi: 10.1177/1471301217744597. Epub 2017 Nov 30. No abstract available.

PMID:
29188730
4.

Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.

McBride JW, Dias N, Cameron D, Offord RE, Hartley O, Boyd P, Kett VL, Malcolm RK.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00965-17. doi: 10.1128/AAC.00965-17. Print 2017 Oct.

5.

Stability of 5P12-RANTES, A Candidate Rectal Microbicide, in Human Rectal Lavage.

Cerini F, Offord R, McGowan I, Hartley O.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):768-777. doi: 10.1089/AID.2016.0199. Epub 2017 Mar 6.

PMID:
28177261
6.

A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.

Cerini F, Gaertner H, Madden K, Tolstorukov I, Brown S, Laukens B, Callewaert N, Harner JC, Oommen AM, Harms JT, Sump AR, Sealock RC, Peterson DJ, Johnson SK, Abramson SB, Meagher M, Offord R, Hartley O.

Protein Expr Purif. 2016 Mar;119:1-10. doi: 10.1016/j.pep.2015.10.011. Epub 2015 Oct 24.

7.

Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.

Fabio K, Curley K, Guarneri J, Adamo B, Laurenzi B, Grant M, Offord R, Kraft K, Leone-Bay A.

AAPS PharmSciTech. 2015 Dec;16(6):1299-306. doi: 10.1208/s12249-015-0314-0. Epub 2015 Mar 17.

8.

The next lease of life.

Offord R.

Health Serv J. 2014 Sep 5;124(6413):Suppl 7. No abstract available.

PMID:
25509485
9.

Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.

Wang NX, Sieg SF, Lederman MM, Offord RE, Hartley O, von Recum HA.

Mol Pharm. 2013 Oct 7;10(10):3564-73. doi: 10.1021/mp3007242. Epub 2013 Aug 26.

10.

CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.

Choi WT, Nedellec R, Coetzer M, Colin P, Lagane B, Offord RE, Hartley O, Mosier DE.

J Virol. 2012 Sep;86(18):10218-20. doi: 10.1128/JVI.00353-12. Epub 2012 Jul 11.

11.

Lifeblood responds to criticisms in Welfare's personal view article.

Stephens-Boal A, Webster S, Carter K, Franklin IM, Gardner B, Hart S, Hunt BJ, Noble S, Offord R.

BMJ. 2012 Jan 17;344:e403. doi: 10.1136/bmj.e403. No abstract available.

PMID:
22252693
12.

Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.

Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE.

PLoS One. 2011;6(7):e22020. doi: 10.1371/journal.pone.0022020. Epub 2011 Jul 8.

13.

Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5.

Pilch-Cooper HA, Sieg SF, Hope TJ, Koons A, Escola JM, Offord R, Veazey RS, Mosier DE, Clagett B, Medvik K, Jadlowsky JK, Chance MR, Kiselar JG, Hoxie JA, Collman RG, Riddick NE, Mercanti V, Hartley O, Lederman MM.

Blood. 2011 Jul 28;118(4):1015-9. doi: 10.1182/blood-2010-05-282509. Epub 2010 Nov 10.

14.

Caring for critically ill children within an adult environment--an educational strategy.

Offord RJ.

Nurs Crit Care. 2010 Nov-Dec;15(6):300-7. doi: 10.1111/j.1478-5153.2010.00411.x.

PMID:
21040261
15.

"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.

Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE.

J Virol. 2010 Jun;84(11):5842-5. doi: 10.1128/JVI.01907-09. Epub 2010 Mar 24.

16.

Comparative proteomic study of the venom of the piscivorous cone snail Conus consors.

Biass D, Dutertre S, Gerbault A, Menou JL, Offord R, Favreau P, Stöcklin R.

J Proteomics. 2009 Mar 6;72(2):210-8. doi: 10.1016/j.jprot.2009.01.019. Epub 2009 Jan 23.

PMID:
19457347
17.

Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge.

Veazey RS, Ling B, Green LC, Ribka EP, Lifson JD, Piatak M Jr, Lederman MM, Mosier D, Offord R, Hartley O.

J Infect Dis. 2009 May 15;199(10):1525-7. doi: 10.1086/598685.

18.

Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

Gaertner H, Cerini F, Escola JM, Kuenzi G, Melotti A, Offord R, Rossitto-Borlat I, Nedellec R, Salkowitz J, Gorochov G, Mosier D, Hartley O.

Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17706-11. doi: 10.1073/pnas.0805098105. Epub 2008 Nov 12.

19.

Chemokine analogues show suitable stability for development as microbicides.

Cerini F, Landay A, Gichinga C, Lederman MM, Flyckt R, Starks D, Offord RE, Le Gal F, Hartley O.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):472-6. doi: 10.1097/QAI.0b013e31818c953f.

PMID:
18989226
20.

Semisynthetic analogues of PSC-RANTES, a potent anti-HIV protein.

Gaertner H, Offord R, Botti P, Kuenzi G, Hartley O.

Bioconjug Chem. 2008 Feb;19(2):480-9. doi: 10.1021/bc7003044. Epub 2008 Jan 8.

PMID:
18179159
21.

Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4.

Gaertner H, Lebeau O, Borlat I, Cerini F, Dufour B, Kuenzi G, Melotti A, Fish RJ, Offord R, Springael JY, Parmentier M, Hartley O.

Protein Eng Des Sel. 2008 Feb;21(2):65-72. doi: 10.1093/protein/gzm079. Epub 2008 Jan 4.

PMID:
18178567
22.

Microbicides and other topical strategies to prevent vaginal transmission of HIV.

Lederman MM, Offord RE, Hartley O.

Nat Rev Immunol. 2006 May;6(5):371-82. Review.

PMID:
16639430
23.

Engineering chemokines to develop optimized HIV inhibitors.

Hartley O, Offord RE.

Curr Protein Pept Sci. 2005 Jun;6(3):207-19. Review.

PMID:
15974948
24.

Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.

Hartley O, Gaertner H, Wilken J, Thompson D, Fish R, Ramos A, Pastore C, Dufour B, Cerini F, Melotti A, Heveker N, Picard L, Alizon M, Mosier D, Kent S, Offord R.

Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16460-5. Epub 2004 Nov 15.

25.

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M Jr, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O.

Science. 2004 Oct 15;306(5695):485-7.

26.

Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.

Offord R, Lloyd AC, Anderson P, Bearne A.

Pharm World Sci. 2004 Aug;26(4):214-20.

PMID:
15446778
27.

PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.

Kawamura T, Bruse SE, Abraha A, Sugaya M, Hartley O, Offord RE, Arts EJ, Zimmerman PA, Blauvelt A.

J Virol. 2004 Jul;78(14):7602-9. Erratum in: J Virol. 2004 Oct;78(19):10837. Bruce, Shannon E [corrected to Bruse, Shannon E].

28.

Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3.

Chvatchko Y, Proudfoot AE, Buser R, Juillard P, Alouani S, Kosco-Vilbois M, Coyle AJ, Nibbs RJ, Graham G, Offord RE, Wells TN.

J Immunol. 2003 Nov 15;171(10):5498-506.

29.

Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.

Hartley O, Dorgham K, Perez-Bercoff D, Cerini F, Heimann A, Gaertner H, Offord RE, Pancino G, Debré P, Gorochov G.

J Virol. 2003 Jun;77(12):6637-44.

31.

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.

Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, Mosier DE.

Antimicrob Agents Chemother. 2003 Feb;47(2):509-17.

32.

Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.

Storto G, Buchegger F, Waibel R, Kuenzi G, Offord RE, Schubiger PA, Gillet M, Delaloye AB.

Cancer Biother Radiopharm. 2001 Oct;16(5):371-9.

PMID:
11776754
33.

Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.

Marozsan AJ, Torre VS, Johnson M, Ball SC, Cross JV, Templeton DJ, Quiñones-Mateu ME, Offord RE, Arts EJ.

J Virol. 2001 Sep;75(18):8624-38.

34.

Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.

Sabbe R, Picchio GR, Pastore C, Chaloin O, Hartley O, Offord R, Mosier DE.

J Virol. 2001 Jan;75(2):661-71.

35.

Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants.

Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB, Orenstein JM, Offord RE, Neurath AR, Blauvelt A.

J Exp Med. 2000 Nov 20;192(10):1491-500.

36.

Management of venous and cardiovascular thrombosis: enoxaparin.

Harvey DM, Offord RH.

Hosp Med. 2000 Sep;61(9):628-36. Review.

PMID:
11048604
37.

Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.

Rusconi S, La Seta Catamancio S, Citterio P, Bulgheroni E, Croce F, Herrmann SH, Offord RE, Galli M, Hirsch MS.

J Virol. 2000 Oct;74(19):9328-32.

38.

Positive and negative labeling of human proinsulin, insulin, and C-peptide with stable isotopes. New tools for in vivo pharmacokinetic and metabolic studies.

Stöcklin R, Arrighi JF, Hoang-Van K, Vu L, Cerini F, Gilles N, Genet R, Markussen J, Offord RE, Rose K.

Methods Mol Biol. 2000;146:293-315. Review. No abstract available.

PMID:
10948509
39.

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.

Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, Offord RE, Quiñones-Mateu ME, Arts EJ.

J Virol. 2000 May;74(10):4868-76.

40.

Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors.

Proudfoot AE, Buser R, Borlat F, Alouani S, Soler D, Offord RE, Schröder JM, Power CA, Wells TN.

J Biol Chem. 1999 Nov 5;274(45):32478-85.

41.

Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation.

Rusconi S, La Seta-Catamancio S, Kurtagic S, Galazzi M, Arienti D, Trabattoni D, Wilken J, Thompson DA, Offord RE, Galli M, Clerici M.

AIDS Res Hum Retroviruses. 1999 Jul 1;15(10):861-7.

PMID:
10408722
42.

Hb Iraq-Halabja beta10 (A7) Ala-->Val (GCC-->GTC): a new beta-chain silent variant in a family with multiple Hb disorders.

Deutsch S, Darbellay R, Offord R, Frutiger A, Kister J, Wajcman H, Beris P.

Am J Hematol. 1999 Jul;61(3):187-93.

43.

Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES.

Rusconi S, Merrill DP, La Seta-Catamancio S, Citterio P, Offord RE, Hirsch MS.

AIDS. 1999 Jun 18;13(9):1144-5. No abstract available.

PMID:
10397549
44.
45.

Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, Offord RE, Thompson DA, Wilken J.

J Virol. 1999 May;73(5):3544-50.

46.

CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction.

Kinter A, Catanzaro A, Monaco J, Ruiz M, Justement J, Moir S, Arthos J, Oliva A, Ehler L, Mizell S, Jackson R, Ostrowski M, Hoxie J, Offord R, Fauci AS.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11880-5.

47.

Short-term insulin-induced glycogen formation in primary hepatocytes as a screening bioassay for insulin action.

Vu L, Pralong WF, Cerini F, Gjinovci A, Stöcklin R, Rose K, Offord RE, Kippen AD.

Anal Biochem. 1998 Aug 15;262(1):17-22.

PMID:
9735143
48.

Elimination of free radionuclide by a chelating agent improves tumor-to-nontumor ratios following radioimmunotargeting with antibody labeled with 67Ga.

Ryser JE, Rose K, Jones R, Pelegrin A, Donath A, Egeli R, Smith A, Offord RE.

Nucl Med Biol. 1998 Apr;25(3):261-5.

PMID:
9620632
49.
50.

The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and 225-Ac in tumor-bearing mice. The ISOLDE Collaboration.

Beyer GJ, Offord R, Künzi G, Aleksandrova Y, Ravn U, Jahn S, Barker J, Tengblad O, Lindroos M.

Nucl Med Biol. 1997 Jul;24(5):367-72.

PMID:
9290069

Supplemental Content

Loading ...
Support Center